Review
Open access
Aug 2026
Emerging targeted therapies for primary immune thrombocytopenia: novel agents, combination strategies, and future directions
This article analyses recent therapeutic trials with Bruton’s tyrosine kinase inhibitors, splenic tyrosine kinase inhibitors, and neonatal Fc receptor antagonists, demonstrating an improvement in platelet counts and patients’ quality of life.
Zhen Wang, Wu-Xia Yang, Nuo Xu et al.
· Frontiers in Pharmacology · 0 citations